Peripheral dopamine receptor antagonist that does not cross the blood-brain barrier; anti-emetic.
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
The American journal of gastroenterology, 102(9), 2036-2045 (2007-05-10)
Domperidone is a dopamine-2 receptor antagonist. It acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine. Unlike metoclopramide, it does not cause any adverse
The Turkish journal of pediatrics, 55(1), 1-7 (2013-05-23)
Gastroesophageal reflux (GER) is a normal physiologic process occurring several times per day in healthy infants. Regurgitation is defined as the passage of refluxed gastric contents into the pharynx or mouth, sometimes with expulsion out of the mouth. There are
Domperidone is a dopamine antagonist that does not readily enter the central nervous system. Given parenterally or orally it increases gastric emptying of liquids and increases lower oesophageal sphincter pressure in healthy subjects. The antiemetic and pharmacodynamic profile of domperidone
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
